Results 91 to 100 of about 15,755 (201)

Daratumumab, bortezomib and dexamethasone for previously treated myeloma—Real‐world outcomes for 2545 patients treated in England

British Journal of Haematology, EarlyView.
Sarah L. Lawton, Mark Bishton, Katherine E. Thackray, Emma Kipps, Dean Smith   +4 more
wiley   +1 more source

International multicentre evaluation of a new anti‐idiotypic anti‐daratumumab for resolving pre‐transfusion interferences

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Daratumumab, a therapeutic human anti‐CD38 monoclonal antibody, improves multiple myeloma outcomes but interferes with pre‐transfusion testing by binding CD38 on reagent red blood cells (RBCs), potentially masking clinically significant alloantibodies.
Arnaud Reggiani, Sofia Lejon Crottet, Sophie Waldvogel, Charlotte Engström, Serelina Coluzzi, Antonella Matteocci, Janis R. Hamilton, Levent Tufan Kumas, Karen M. K. de Vooght, Jill R. Storry, Jennylyn Flores, Núria Nogués, Carlos Cotorruelo, Molly Rutherford, Eveline B. Nilsen, Monika Pelc‐Kłopotowska, Jolanta Korzeniowska, Alessandra Baffa, Inna Sareneva, Nor Hafizah Ahmad, Katarzyna Szczudlo, Athif Rahman, Laser Sanal, Lise Jørgensen, Karolina Majewska Rochowiak, Monika Salwierz, Elisaveta Grancharova, Bojana Zivkovic, Jessica Alvarez, Mareike Riedl, Achim Knappik   +30 more
wiley   +1 more source

Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions. [PDF]

, 2019
Despite the many prospective randomized trials that have been available in the past decade regarding the optimization of radiation, hormonal, and surgical therapies for high-risk prostate cancer (PCa), many questions remain.
Chen, Victor E., Den, Robert B., Greenberger, Benjamin A.   +2 more
core   +1 more source

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma

BMC Cancer
Background Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with direct on-tumor and immunomodulatory mechanisms of action. Daratumumab-based treatment is a standard of care for multiple myeloma (MM) based on data from randomized controlled
Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu   +17 more
doaj   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, Volume 116, Issue 6, Page 697-708, June 2026.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real‐World Evidence in a Rapidly Evolving Therapeutic Landscape

European Journal of Haematology, Volume 116, Issue 6, Page 928-936, June 2026.
ABSTRACT Modern therapies have clearly marked the history of multiple myeloma (MM), leading to undisputed advantages in terms of sustained responses and prolonged survival, while progressively improving patients' quality of life. Nonetheless, disease recurrence and resistance to available therapies underscore the importance of identifying additional ...
K. Mancuso, S. Masci, M. Talarico, A. Vitale, S. Barbato, V. Solli, M. Puppi, I. Rizzello, L. Pantani, P. Tacchetti, M. Iezza, R. Restuccia, I. Sacchetti, E. Manzato, S. Ghibellini, S. Armuzzi, B. Taurisano, M. Cavo, E. Zamagni   +18 more
wiley   +1 more source

Engineering tandem VHHs to target different epitopes to enhance antibody‐dependent cell‐mediated cytotoxicity

FEBS Open Bio, Volume 16, Issue 5, Page 1030-1043, May 2026.
Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu, Hao Jiang, Limin Chen, Fulai Zhou, Ying Jin, Mark L. Chiu   +5 more
wiley   +1 more source

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

Haematologica, 2015
Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated cytotoxicity is an important effector mechanism of daratumumab, we explored the possibility of improving daratumumab-mediated ...
Inger S. Nijhof, Jeroen J. Lammerts van Bueren, Berris van Kessel, Pascale Andre, Yannis Morel, Henk M. Lokhorst, Niels W.C.J. van de Donk, Paul W.H.I. Parren, Tuna Mutis   +8 more
doaj   +1 more source

NAD+‒circadian rhythm coupling in dementia

Alzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract The circadian rhythm system and sleep coordinate whole‐body functions across the 24‐h cycle, yet these rhythms progressively deteriorate with neurodegenerative diseases, including dementia. Growing evidence indicates that nicotinamide adenine dinucleotide (NAD+) interacts with the circadian system through multiple molecular pathways and that ...
Shi‐qi Zhang, Jiyeon Lee, Jun‐ping Pan, Rune Enger, Harald Hrubos‐Strøm, Erik S. Musiek, Evandro Fei Fang, Weidong Le   +7 more
wiley   +1 more source